Adam Marcus PhD
Overview
Adam Marcus, PhD, is Winship 5K Research Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Marcus serves as deputy director for Winship Cancer Institute of Emory University, leading the integration of the research, clinical, and educational components within Winship. He also previously served as associate director of basic research and shared resources, and in 2021 served as interim executive director of Winship Cancer Institute of Emory University. He has provided senior leadership oversight of the current Cancer Center Support Grant (CCSG) planning process and contributed to Winship's successful CCSG submissions in 2011 and 2016.
Dr. Marcus has previously served as associate vice president for research in Emory University's Woodruff Health Sciences Center, and as associate dean for novel technology and research cores leading the Emory Integrated Core Facilities and Division of Animal Resources.
Dr. Marcus also previously served as scientific director for 18 years of the Emory Integrated Cell Imaging Core, a jointly managed shared resource of Winship Cancer Institute and Emory University School of Medicine.
Dr. Marcus joined the faculty at Winship Cancer Institute in 2006, and developed his own laboratory which focuses on cell biology and pharmacology in lung and breast cancer. He is a national leader in understanding how cancer cells invade and metastasize and how to apply this knowledge in developing new therapeutic strategies.
Dr. Marcus has led a long-standing effort to stimulate critical thinking and enthusiasm for sciences in children from kindergarten through 12th grade in the state of Georgia. In addition, he collaborates with Theresa Gillespie, PhD, to increase underrepresented minority participation in STEM with a focus on middle-school students through grant support from the National Institutes of Health.
Academic Appointment
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- PhD from Pennsylvania State University, Hershey
- BS from Binghamton University, Binghamton
Research
Focus
- Our research is focused on the molecular mechanisms that guide lung and breast cancer metastasis, with an emphasis on cell adhesion and polarity. We are currently using this information to develop novel anti-metastatic agents that target the cytoskeleton and basic adhesion/motility pathways.
Publications
-
TGF-1-mediated intercellular signaling fuels cooperative cellular invasion.
Cell Rep Volume: 44 Page(s): 115315
02/25/2025 Authors: Khatib TO; Pedro BA; Bombin S; Matsuk VY; Robinson IE; Webster SF; Marcus LJ; Summerbell ER; Tharp GK; Knippler CM -
Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer.
bioRxiv
06/14/2023 Authors: Koo J; Seong C-S; Parker RE; Dwivedi B; Arthur RA; Dinasarapu AR; Johnston HR; Claussen H; Tucker-Burden C; Ramalingam SS -
A live-cell platform to isolate phenotypically defined subpopulations for spatial multi-omic profiling.
bioRxiv
03/01/2023 Authors: Khatib TO; Amanso AM; Pedro B; Knippler CM; Summerbell ER; Zohbi NM; Konen JM; Mouw JK; Marcus AI -
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.
bioRxiv
01/27/2023 Authors: Seong C-S; Huang C; Boese AC; Hou Y; Koo J; Mouw JK; Rupji M; Joseph G; Johnston HR; Claussen H -
Crosstalk Between Cancer Associated Fibroblast Soluble Mediators and Pancreatic Cancer Cells Facilitate an Invasive Phenotype
Volume: 50 Page(s): 1061 - 1061
08/01/2021 Authors: Greene E; Ware M; Herting C; Maithel S; Sarmiento J; El-Rayes BF; Tucker-Burden C; Marcus A; Lesinski GB -
Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
Lung Cancer Volume: 154 Page(s): 228
04/01/2021 Authors: Mao K; Liu F; Liu X; Khuri FR; Marcus AI; Li M; Zhou W -
Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
Lung Cancer Volume: 154 Page(s): 227
04/01/2021 Authors: Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun S-Y; He Y; Zhou W -
Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis.
Mol Cancer Ther Volume: 20 Page(s): 274 - 283
02/01/2021 Authors: Jin R; Liu B; Liu X; Fan Y; Peng W; Huang C; Marcus A; Sica G; Gilbert-Ross M; Liu Y -
Epigenetically heterogeneous tumor cells direct collective invasion through filopodia-driven fibronectin micropatterning.
Sci Adv Volume: 6 Page(s): eaaz6197
07/01/2020 Authors: Summerbell ER; Mouw JK; Bell JSK; Knippler CM; Pedro B; Arnst JL; Khatib TO; Commander R; Barwick BG; Konen J -
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q.
Cancer Volume: 126 Page(s): 3140 - 3150
07/01/2020 Authors: Pedro B; Rupji M; Dwivedi B; Kowalski J; Konen JM; Owonikoko TK; Ramalingam SS; Vertino PM; Marcus AI